Kallen, Karl-Josef

Developing mRNA-vaccine technologies

Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K.-J. (2012) · RNA Biology

RNA Interference and Gene DeliveryImmunotherapy and Immune Responses

Cited by 622

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection

Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology

Influenza Virus Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 464

Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE)

Matthews, V., Schuster, B., Schütze, S., Bussmeyer, I., Ludwig, A., Hundhausen, C., Sadowski, T., Saftig, P., Hartmann, D., Kallen, K.-J., et al. (2003) · Journal of Biological Chemistry

Cytokine Signaling Pathways and InteractionsProtease and Inhibitor Mechanisms

Cited by 390

Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity

Fotin-Mleczek, M., Duchardt, K. M., Lorenz, C., Pfeiffer, R., Ojkić-Zrna, S., Probst, J., & Kallen, K.-J. (2011) · Journal of Immunotherapy

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 335

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

Kübler, H., Scheel, B., Gnad-Vogt, U., Miller, K., Schultze-Seemann, W., vom Dorp, F., Parmiani, G., Hampel, C., Wedel, S., Trojan, L., et al. (2015) · Journal for Immunotherapy of Cancer

Immunotherapy and Immune ResponsesProstate Cancer Treatment and Research

Cited by 287

A novel, disruptive vaccination technology: Self-adjuvanted RNActive ® vaccines

Kallen, K.-J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., Baumhof, P., Scheel, B., Koch, S. D., & Fotin-Mleczek, M. (2013) · Human Vaccines & Immunotherapeutics

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 223

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

Sebastian, M., Schröder, A., Scheel, B., Hong, H. S., Muth, A., von Boehmer, L., Zippelius, A., Mayer, F., Reck, M., Atanackovic, D., et al. (2019) · Cancer Immunology, Immunotherapy

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 209

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect

Fotin‐Mleczek, M., Zanzinger, K., Heidenreich, R., Lorenz, C., Thess, A., Duchardt, K. M., & Kallen, K. (2012) · The Journal of Gene Medicine

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 103

Murine Liver Antigen Presenting Cells Control Suppressor Activity of CD4+CD25+ Regulatory T Cells *

Wiegard, C., Frenzel, C., Herkel, J., Kallen, K.-J., Schmitt, E., & Lohse, A. W. (2005) · Hepatology

T-cell and B-cell ImmunologyLiver physiology and pathology

Cited by 97

Lack of gp130 expression in hepatocytes promotes liver injury1 1K.L.S. and T.W. contributed equally to this work.

StreetZ, K. L., Wüstefeld, T., Klein, C., Kallen, K.-J., Tronche, F., Betz, U. A. K., Schütz, G., Manns, M. P., Müller, W., & Trautwein, C. (2003) · Gastroenterology

Cytokine Signaling Pathways and InteractionsLiver physiology and pathology

Cited by 94

Messenger RNA vaccination and B-cell responses in NSCLC patients.

Sebastian, M., von Boehmer, L., Zippelius, A., Mayer, F., Reck, M., Atanackovic, D., Thomas, M., Schneller, F., Stoehlmacher-Williams, J., Goekkurt, E., et al. (2012) · Journal of Clinical Oncology

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 13